Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
15 Februar 2024 - 10:30PM
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial
Results on March 5, 2024
Nyxoah to Release Fourth Quarter and
Financial Year 2023 Financial Results on March 5,
2024
Mont-Saint-Guibert, Belgium – February
15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext
Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a
medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive
Sleep Apnea (OSA), today announced that the Company will release
financial results for the fourth quarter and financial year 2023 on
Tuesday, March 5, 2024, after market close. Company management will
host a conference call to discuss financial results that day
beginning at 10:30pm CET / 4:30pm ET.
A webcast of the call will be accessible via the
Investor Relations page of the Nyxoah website or through this link:
Nyxoah's Q4 2023 earnings call webcast. For those not planning to
ask a question of management, the Company recommends listening via
the webcast.
If you plan to ask a question, please use the
following link: Nyxoah’s Q4 2023 earnings call. After registering,
an email will be sent, including dial-in details and a unique
conference call access code required to join the live call. To
ensure you are connected prior to the beginning of the call, the
Company suggests registering a minimum of 10 minutes before the
start of the call.
The archived webcast will be available for
replay shortly after the close of the call.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Following the positive outcomes of the BETTER SLEEP study, Nyxoah
received CE mark approval for the expansion of its therapeutic
indications to Complete Concentric Collapse (CCC) patients,
currently contraindicated in competitors’ therapy. Additionally,
the Company is currently conducting the DREAM IDE pivotal study for
FDA and U.S. commercialization approval.
For more information, please visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Contacts:NyxoahDavid DeMartino,
Chief Strategy Officerdavid.demartino@nyxoah.com+1 310 310 1313
- ENGLISH_Q4 2023 Earnings Call Save-the-Date
Nyxoah (EU:NYXH)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Nyxoah (EU:NYXH)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
